Other fibrinolytic impairments include increased incorporation of α2AP into fibrin clots [128], elevated FDPs [129], and higher circulating levels of α2AP, particularly in those with diabetic nephropathy (DN) [130]. Here, SERPINF2 is linked to liver dysplastic nodule.